Publication | Open Access

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer

MedicineClinical TrialsBronchial NeoplasmPharmacotherapyCancer TreatmentOncologyRadiation OncologyLung CancerHealth Sciences